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Abstract  
 The use of non-invasive prenatal testing (NIPT) for aneuploidy screening has increased 
dramatically in the last five years due to its high sensitivity and specificity. However, testing cell 
free fetal DNA (cffDNA) opens the door to maternal incidental findings. This study aims to assess 
genetic counselors’ preparedness to respond to such incidental findings by surveying prenatal 
genetic counselors about their experiences with these cases. Surprisingly, 62% of  the prenatal 
genetic counselors (89/143) in this study have encountered incidental findings in their practice, 
and many shared accounts of unique cases. In addition, participants were asked to respond to three 
hypothetical scenarios: an incidental finding of maternal mosaicism for Turner syndrome (45, XO) 
for which 83% of respondents felt “very prepared” to manage; an incidental finding of a maternal 
microdeletion, for which 72% of respondents felt “very prepared”; and an incidental finding of 
maternal malignancy, for which only 48% of respondents felt “very prepared” to handle. There 
was a statistically significant difference between the first two scenarios and the third, with 
participants feeling least prepared to manage an incidental finding of maternal malignancy.  
Participants were also surveyed about their interactions with testing labs, with 34% of respondents 
stating they had received results informally from the lab, and of those, 70% relayed those results 
to patients. Overall, genetic counselors felt prepared to counsel patients on incidental findings of 
maternal mosaicism and maternal microdeletions, yet unprepared to counsel patients on an 








The most common cause of miscarriage and congenital birth defects is the presence of extra 
chromosomes in each cell of the individual (Carlson & Vora, 2017).  Common chromosomal 
abnormalities include trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 
13 (Patau syndrome) in which an extra chromosome 21, 18, or 13 is present in each cell, 
respectively. Sex chromosome aneuploidies, such as monosomy X (Turner syndrome) and 
Klinefelter syndrome (47, XXY), are also relatively common (Carlson & Vora, 2017).   Down 
syndrome has a high prevalence (affecting 1 in 800 newborns) [Carlson & Vora, 2017]) and Patau 
and Edwards syndromes are associated with severe life-threatening birth defects, therefore is it 
recommended that all patients be offered aneuploidy screening prenatally (Committee on Genetics, 
Society for Maternal-Fetal Medicine, 2017). Early diagnosis gives prospective parents the time 
and opportunity to make decisions about pregnancy termination or prepare for the birth of child 
with complex medical needs.  
In general, both patients and physicians prefer non-invasive aneuploidy screening to avoid 
the risk of miscarriage associated with invasive diagnostic testing (Wilson et al., 2013). 
Traditionally, techniques such as the first trimester screen, quad screen, and ultrasound monitoring 
have been used to identify high-risk pregnancies. Invasive techniques such as chorionic villus 
sampling (CVS) and amniocentesis are diagnostic and may be offered to all pregnant women 
regardless of whether they are at low- or high-risk (Committee on Genetics, Society for Maternal-
Fetal Medicine, 2017).  
Recently, a new method of aneuploidy screening was developed called non-invasive 
prenatal testing (NIPT) using cell free fetal DNA (cffDNA). NIPT has become popular among 
patients and providers because it has higher sensitivity and specificity than other available screens. 
In addition, some versions of NIPT screen for sex chromosome abnormalities and common 
microdeletions, although these tests have lower degrees of sensitivity and specificity (Committee 
on Genetics, Society for Maternal-Fetal Medicine, 2017). The introduction of these more advanced 
tests has decreased the need for invasive procedures and increased the likelihood of incidental 
findings such as maternal malignancy or maternal conditions. These findings create difficult 
situations for both patients and healthcare providers, because there are no available guidelines on 
appropriate management.  
 
 
Incidental findings due to discordant NIPT results 
Though clearly a powerful screening tool, several unexpected challenges have followed 
NIPT’s introduction to the clinical setting; particularly challenging are discordant results (a 
positive result on NIPT and a normal fetal karyotype). In a 2015 study by Illumina of 18,161 NIPT 
results, 32 were found to be discordant with respect to fetal sex reported by karyotype/ultrasound. 
Four of the 32 discordant results were due to unique circumstances: patient’s history of kidney 
transplantation from a male donor giving rise to XY NIPT result when the fetus was in fact female;  
co-twin demise; and fetal ambiguous genitalia (Bianchi, Parsa, et al., 2015). 
Another cause of discordant results is previously unidentified genetic variations in the 
mother.  An incidental finding is defined as information produced by a test which may have clinical 
implications but is unrelated to the initial indication for testing (Smith et al., 2015). Incidental 
findings – including maternal mosaicism, maternal chromosomal abnormalities, and maternal 
malignancy – have been reported in patients who had NIPT and warrant new consideration of 
NIPT in clinical practice. Many questions remain about the best ways to conduct informed consent 
for NIPT, discuss the possibility of incidental findings, and interpret and report incidental findings 
when they occur. 
 
 Mosaicism 
         Mosaicism is a phenomenon in which an individual has two genetically different cell lines 
within their body. This is typically caused by mitotic nondisjunction occurring early in 
development. Mosaicism can occur in the woman carrying the pregnancy, in the fetus, or in the 
placenta.  Since a common method of NIPT (MPSS-based) does not discriminate between maternal 
and fetal DNA, maternal mosaicism is a major contributor to discordant test results, and ultimately 
incidental maternal findings. Another source of discrepancy comes in the form of confined 
placental mosaicism (CPM) in which the fetus and the placenta have differing cell lines despite 
having the same embryonic origin. CPM occurs in 1-2% of viable pregnancies, but it can cause 
false positive NIPT results. CPM would not be considered an incidental finding, because it is 
related to the indication for testing. Maternal mosaicism, however, would be an incidental finding. 
         In a 2014 study, researchers looked at sex chromosome aneuploidies (SCA) identified via 
NIPT (Wang et al., 2014). Out of 187 abnormal results, sixteen (8.5%) were due to altered or 
mosaic karyotype of the mother (Wang et al., 2014). This study demonstrated that maternal 
mosaicism can cause discordant NIPT results, potentially leading to patients discovering they are 
mosaic for Turner syndrome. The incidence of mosaic Turner syndrome increases in frequency as 
a woman ages (Machiella et al., 2016); however. age-related mosaicism is generally asymptomatic 
(Russell et al., 2007).  
The incidental finding of maternal mosaicism becomes challenging when the patient is not 
aware of their mosaic status. Although generally benign, maternal mosaicism may affect future 
family planning or lead to the discovery of previously undiagnosed conditions. Clinicians must 
decide whether to include the possibility of uncovering such results in their pre-test counseling 
discussions regarding NIPT.  
 
Maternal Conditions 
Newer versions of NIPT offer patients the opportunity to screen for common microdeletion 
syndromes, such as Prader-Willi/Angelman syndrome, Cri-du-chat syndrome, and 22q11.2 
deletion syndrome. There is limited data regarding the sensitivity and specificity of these tests, but 
they have already been taken up by many providers due to the severity of the conditions and the 
non-invasiveness of the screening methodology. The addition of microdeletion screening to NIPT 
introduces the chance of incidentally finding a maternal condition. The most common such 
incidental finding reported in the literature is maternal 22q11.2 deletion syndrome. McDonald-
McGinn et al (2001) estimated that 10% of cases of 22q11.2 deletion syndrome were inherited. 
For this reason, parental testing is recommended for all patients diagnosed with this syndrome 
(McDonald-McGinn & Zackai, 2008). 
A study published in 2016 found that of 97 pregnancies reported as high-risk for 22q11.2 
deletion syndrome via NIPT, two were suspected to be of maternal origin: one was confirmed by 
diagnostic testing and the other was lost to follow-up, though the latter patient had previously lost 
a pregnancy affected with 22q11.2 deletion syndrome (Gross et al., 2016). The authors did not 
elaborate on how these findings were received by the patients.  
The implications of an incidental finding of a maternal condition could be much more 
significant than those of maternal mosaicism, creating challenges for conducting informed consent 
and reporting of NIPT results. It is unclear whether knowledge of this possibility is essential to 
informed consent, or whether genetic counselors should discuss the possibility only following a 
positive result. Others may argue that NIPT is not validated to diagnose maternal conditions, and 
therefore it should not be discussed at all. The most recent guidelines from the American College 
of Medical Genetics offer no clear instructions regarding incidental findings, other than 
recommending that providers discuss the possibility with patients (Gregg et al., 2016). 
  
Maternal Malignancy 
Cancer is a disease caused by the accumulation of mutations, which may progress to 
abnormalities in chromosome number. DNA from cancer cells can be shed into the bloodstream, 
and there, much like cffDNA, can be identified by NIPT.  The chromosomal abnormalities emitted 
by tumor cells are often of such aberrant formation that they could not be produced by a viable 
fetus.  When such findings arise in the setting of cffDNA screening during pregnancy, this can 
lead to challenging situations regarding interpretation of results, communication of the results to 
patients, and medical management. 
Identifying maternal malignancy via NIPT has been documented in the literature. In a 2015 
study, researchers looked at 125,426 samples from women who underwent NIPT for aneuploidy 
screening of chromosomes 13,18, 21, X, and Y. Of those, 3,757 had positive results and underwent 
invasive testing. Of the 3,757 positive results, ten women whose NIPT results were discordant 
with the invasive testing were later diagnosed with cancer after further medical examination 
(Bianchi et al., 2015). Another study published in 2015 reported that, in 4,000 pregnant patients 
who underwent NIPT, three women were found to have “aberrant genome representation profiles” 
consistent with cancer. These women were subsequently referred for whole-body MRI, which 
revealed tumors in all three women (Amant et al., 2015). Both studies demonstrated that NIPT 
could detect malignancy in women during pregnancy, leading to very real and unexpected 
outcomes for these patients.  However, neither study offered insight into how providers discussed 
these results with the patients. 
      Earlier this year, a study was published which surveyed over 300 genetic counselors about 
their experiences with NIPT and views on reporting results which could indicate maternal 
malignancy. The results indicated that 95% of respondents were aware that NIPT results could 
indicate maternal malignancy. There was less agreement about how to counsel and follow patients 
with these suspicious results: 77% reported they would disclose such results to patients if they 
were not documented clearly in the report from the lab, yet nearly all genetic counselors surveyed 
stated that they would disclose the finding if it were clearly documented on the test report. More 
than half of respondents reported that they would not feel comfortable counseling this type of 
session (Giles et al., 2017).  When asked how they would follow a patient with this result, 
participants gave a variety of responses, including referring to oncology, referring to OB/MFM, or 
primary care physician; repeat NIPT; and invasive testing.  Most (91%) stated they would need 
more data and guidelines. This study also surveyed respondents on the content of their pre-test 
counseling sessions for NIPT, with only one third mentioning the possibility of rare, unexpected 
results (Giles et al., 2017).  This survey indicated that genetic counselors were willing to disclose 
incidental findings to patients but were eager for more guidance and data to inform their approach. 
Although this study was informative and novel, it focused on maternal malignancy and did not 
collect opinions regarding other incidental findings such as maternal conditions or maternal 
mosaicism (Giles et al., 2017). 
The above research illustrates the complicated situations which can follow discordant NIPT 
results and highlights the need for more guidance on management of incidental findings in the 
clinic. The opinions and experiences of genetic counselors who have dealt with incidental findings 
from NIPT will be an essential contribution to such guidelines. The purpose of this study is to 
understand how genetic counselors are currently handling incidental findings from NIPT, and how 
prepared the genetic counseling field is to handle them in the future.  
 
Methods 
An online survey was designed to collect genetic counselors’ experiences and opinions of handling 
incidental findings from NIPT.  An email invitation to participate in the study included a link to 
the survey and was sent to the National Society of Genetic Counselors’ listserv. All genetic 
counselors who had counseled in a prenatal setting at any point in their career were eligible to 
participate. All data was collected anonymously. This survey gathered participants’ demographic 
information, experiences in counseling in the prenatal setting, and their responses to three 
hypothetical scenarios of incidental findings. The survey included a combination of close-ended 
and open-ended questions. 
The scenarios targeted three circumstances of incidental findings from NIPT: maternal 
mosaicism, maternal microdeletion, and maternal malignancy.  In the first scenario, the possibility 
of NIPT revealing maternal mosaicism for 45,XO (Turner syndrome) was introduced. This 
scenario was considered low stakes because maternal mosaicism for 45,XO is relatively common 
in older women who can spontaneously shed an X chromosome from some cells with no health 
implications.  The second scenario described a false positive NIPT result for 22q11.2 deletion 
syndrome. This scenario increases the stakes because a diagnosis of 22q11.2 in the patient would 
change reproductive risks for future pregnancies and likely introduce new medical 
management/surveillance of the mother for cardiac defects and other abnormalities associated with 
this condition.  The third scenario was designed to examine genetic counselors’ responses to NIPT 
results showing possible maternal malignancy. In this case, the results of the NIPT indicated a high 
risk for monosomy 13 and trisomy 18. Compared to the first two, this scenario was crafted to have 
more serious medical implications for the woman and fewer established guidelines for 
management.   
Each scenario was followed by a series of questions regarding results disclosure and  
follow-up, including questions such as: “How prepared do you feel to counsel this patient?”, 
“Would you contact the performing lab to inquire about these results?”, “When would you discuss 
the possibility that NIPT could reveal incidental findings with the patient?”, “What further genetic 
testing would you recommend?”, “Would you discuss these results with the lab?”, “What is your 
experience with a scenario like this?”, and “Would you discuss with the patient the future medical 
impact of these results?”  These questions were not meant to test participants’ knowledge, but 
rather to assess how consistent responses were across the study sample. A Chi Square test was 
used to assess relationships between responses to questions. 
 
Results 
The survey yielded 183 respondents, of which 93.99% (172/183) were Caucasian, 0.55% (1/182) 
Black, 1.64% (3/183) Hispanic, 3.28% (6/183) Asian, and 0.55% (1/183) who identified as Other; 
95.05% (174/183) identified as female. Further demographic information can be found in Table I 
and Table II.  
The most common reason for referral noted by respondents was advanced maternal age. 
As shown in Figure 1, respondents ordered NIPT from a wide variety of companies. During pretest 
counseling, 42% of respondents routinely discussed the possibility of incidental findings, while 
28% did not and 29% sometimes discussed the possibility. Figure 2 shows the specific types of 
incidental findings that genetic counselors mentioned during informed consent.  For those who did 
not discuss incidental findings during pretest counseling, Figure 3 shows the various reasons they 
selected, the most common of which was that an incidental finding is a rare occurrence. 
In response to the question, “Do you regard the lab performing NIPT as a useful resource 
when clarifying discordant NIPT results which suggest an incidental finding?”, 67% answered yes, 
3% answered no, and 30% answered somewhat. In addition, 11 people elaborated in the comments 
section that their answer would depend on which lab they were using.  
As shown in Figure 4, 33% (46/143) of respondents had encountered maternal mosaicism, 
39% (56/143) had encountered a maternal condition, and 21% (30/143) had encountered maternal 
malignancy; 38% (54/143) had not encountered any incidental findings in their practice.  
Regarding informal reporting, 34% of respondents stated they had received results 
informally from the lab, and of those, 70% had relayed those results to patients. Genetic counselors 
had mixed responses to informal reporting by the lab, with 30% of respondents remarking about 
requesting a formal report from the lab. One response in this category was as follows: “I have 
argued to them that they should not report anything to me verbally that they are not willing to put 
in writing. This places me at a liability.”  Many were worried about the ethical and legal 
implications of such informal reporting; 19% said that this put them in an uncomfortable position.  
One person said they would “collect as much information as possible and share information with 
the patient. It would feel immoral to withhold that information from the patient.” In contrast, 18% 
said they would thank the lab for giving them the information. Another stated, “I would be 
receptive to their insight and would reach out to colleagues and any relevant journal articles to 
further assess.”  
Scenario 1: Maternal mosaicism 
In response to the scenario on maternal mosaicism, 83% (124/150) felt very prepared to counsel 
this patient, 16% (24/150) felt somewhat prepared, and only 1% (2/150) felt not at all prepared.  A 
slight majority (58%, 87/150) stated they would contact the performing lab to inquire about the 
results, while 42% (63/150) would not. Two thirds (66%, 99/150) would recommend a maternal 
karyotype, while 27% (41/150) would not recommend any further testing.  
In the open-ended questions, several genetic counselors described their experiences with 
this finding. One said: 
“My two patients that ended up having X mosaicism had low level (~4-5%) XO mosaicism 
in blood that was likely due to maternal age-related X dropout, and they were appreciative 
knowing the potential ways this could affect screening in future pregnancies.”  
However, not all genetic counselors felt comfortable with this scenario. Another respondent said: 
“I wish you had an "I don't know" option, these scenarios are not easy to deal with and I 
honestly don't think I would have even thought of the possibility of maternal mosaicism.”  
Another genetic counselor explained her approach as follows:  
“I would offer a maternal karyotype but only if the mother is interested in learning more 
about her own health; she may have or may not have reasons to investigate or want NOT 
to know.” 
One genetic counselor gave her opinion on her experience with patients’ reactions to maternal 
mosaicism: 
“Most women are not that concerned if they are asymptomatic. In some cases, the mosaic 
NIPS result validates concerns the patient has always had but patients do not seem 
negatively concerned when counseled appropriately.” 
Scenario 2: Maternal condition 
In the second scenario where NIPT leads to a suspicion of 22q11.2 deletion syndrome in the 
mother, 72% (104/145) felt very prepared to counsel this patient, 26% (37/145) felt somewhat 
prepared, and 1.38% (2/145) felt not at all prepared. When asked about disclosure to the patient, 
12% (17/145) said that they would not discuss the possibility that NIPT could reveal a maternal 
condition. The majority (74%, 108/145) would contact the performing lab to inquire about the 
NIPT results, and most would recommend further testing in the form of a microarray or FISH (see 
Figure 5). There were a variety of answers to the question of further management 
recommendations for the potential maternal 22q11.2 deletion syndrome as seen in Figure 6, though 
52% stated that they would make a referral to Genetics. Approximately a third (31%) chose the 
“Other” category to stipulate that they would not make any recommendations until the maternal 
condition was confirmed. 
Several respondents described experiences similar to the scenario presented. One in-depth 
experience was particularly noteworthy:  
“[The] patient was referred to our fetal care center for suspected 22q deletion in her fetus. 
NIPT...had been previously drawn by her referring OB d/t suspected fetal TOF and came 
back high risk for 22q deletion. Pt came to our fetal center and had a normal fetal echo. 
Family was relieved thinking that since the heart was normal, the 22q was probably a false 
positive. Apparently no one had looked at the report from her referring MD's office closely 
because the result said fetus was expected to be at 50% risk for 22q d/t suspected maternal 
deletion. When I met with the patient, she was clearly dysmorphic and reported a history 
of learning disabilities. At that point I had to go back and discuss the technology behind 
[NIPT], what her results actually suggested, and explain that I felt it was likely she had 
22q deletion syndrome herself. Patient took it pretty well, agreed to maternal FISH which 
confirmed deletion in her. We recommended that pt have echo and some thyroid tests which 
were all normal. I also made sure to educate the referring MD office about how to deal 
with those types of results in the future. She declined amnio but agreed to 22q FISH on 
cord blood which confirmed deletion in her baby.”  
Some genetic counselors viewed this incidental finding as a benefit to patients. For example one 
respondent said, 
“Patients seem to appreciate this information and it often validates concerns the family 
has already had. Plus, they appreciate that this gives them more accurate recurrence risk 
information, etc.”  
Another’s comment about the occurrence of 22q11.2 deletion syndrome highlighted that 
incidentally finding a maternal condition may not be as rare as genetic counselors may believe 
them to be: 
“Happens more frequently at my clinic because we have a fetal center and get a lot of 
babies with congenital heart detects where mom refuses amniocentesis for prenatal 
diagnosis. I can think of 5 off the top of my head where we were very suspicious that mom 
had 22q and some we then were able to confirm.” 
Several more genetic counselors commented on the positive predictive value: “If the fetal testing 
was negative, I would not offer further work-up. The PPV for 22q11.2 via NIPT is only 20%”, 
meaning that the counselor would understandably assume that the NIPT produced a false positive 
result. Another commented, “Without being prompted to suspect mom and in the context of a 
completely normal medical history for her, I wouldn't jump straight to thinking about testing mom 
given the low PPV for microdeletions on NIPT”. For these same reasons, a genetic counselor 
mentioned being hesitant to order this testing in the first place: “I don’t often order 22q because it 
is unknown how often maternal conditions are picked up, as well as the PPV altogether.” 
Scenario 3: Maternal malignancy 
In response to the maternal malignancy scenario, there was a steep drop in response rate, with only 
52 genetic counselors completing the questions for this scenario. Of those who did, 48% (25/52) 
felt very prepared to counsel the patient and 52% (27/52) felt somewhat prepared. The vast 
majority (92%) indicated they would contact the performing lab. Figure 7 shows great variability 
in when genetic counselors would first discuss the possibility that NIPT could reveal maternal 
malignancy.  
Several participants gave examples of cases similar to this scenario. One genetic counselor 
said,  
“Received phone call from lab indicating that results were not consistent with indication 
for testing and would be technically reported as ‘non-reportable’. GC from lab offered to 
send poster regarding maternal malignancies identified through cfDNA. Patient had family 
history of breast cancer and BRCA mutation, although patient had not undergone testing 
herself. Informed MFM and patient's primary OB of results of testing and conversation 
with lab GC prior to contacting the patient. Upon contacting patient told her that results 
could indicate something benign, but that similar results had also been identified in 
individuals with cancer. Patient stated she had been noticing an increased in breast lumps 
and had been putting off seeing her breast surgeon (whom she was already established 
with given family history), but that this testing was incentive to get in with breast surgeon 
ASAP. Within a couple of weeks she was diagnosed with breast cancer and found to be 
BRCA1 positive. She underwent neoadjuvant chemotherapy and then surgery and 
additional treatments after delivery.”  
A less dramatic account of this type of incidental finding was, “maternal fibroids but not 
malignancy - referred her for whole body MRI.” Another genetic counselor said, “This has come 
up many different times (too many to give specifics on each). Possible malignancy gets direct 
referral to cancer clinic for evaluation.”  
One of the respondents reflected on their role as a genetic counselor, saying  
“I mention the possibility of a whole-body MRI but I don't know that it is within my scope 
to ‘recommend’ it. Then again, I suppose I don't know whose scope it's within if not mine.” 
 
Statistical Analysis 
There were several factors associated with increased perception of preparedness to handle 
incidental findings from NIPT. Seeing a large number of patients per week was one factor 
associated with increased preparedness; all (100%, 11) of the genetic counselors who saw 21 or 
more patients in a week felt very prepared for scenario 1, while 30% (15) of those who saw 11 or 
fewer patients felt only somewhat prepared (p<0.05).  Discussing incidental findings during pretest 
counseling was also associated with higher levels of preparedness; including the possibility of 
maternal mosaicism in pretest counseling meant higher levels of perceived preparedness in 
response to Scenario 1 ( p<0.05). This association was also significant for those responding to 
Scenario 3 (p<0.05). In addition, referring to the rarity of  incidental findings as a reason for not 
discussing incidental findings with patients was related to lower perceived preparedness for 
Scenario 3 (p<0.05).   
In comparing preparedness for the three scenarios, 82.4% (98) were very prepared for 
Scenario 1 and Scenario 2, yet only 56.6% (25) felt very prepared for Scenario 1 and Scenario 3, 
a difference that was significant (p<0.001). Throughout the statistical analysis, there was a 
different pattern of associations for Scenario 3 (maternal malignancy) as compared to Scenarios 
1 and 2. The variable of years as a genetic counselor was not associated with feeling prepared for 
Scenarios 1 or 2; however, it was related to Scenario 3.  Only 23.8% (5) of those in practice for 5 
years or less felt very prepared for Scenario 3, while 60.0% (6) of those in practice for 6 to 10 
years and 66.7% (14) of those in practice 11 or more years felt very prepared for this case 
(p<0.05).  
Feeling prepared for Scenario 1 and Scenario 2 was not related to discussing incidental 
findings during pre-test counseling. However, preparedness for Scenario 3 was related to having 
discussed incidental findings during the pre-test counseling and having counseled a patient with 
this finding (p<0.05).  Three quarters (75.0%, 9/12) of those who had encountered maternal 
malignancy felt very prepared while only 40.0% (16) of those who had not encountered this 
condition felt very prepared to counsel this patient. 
 
Discussion 
Scenario 1: Maternal mosaicism 
Overall, genetic counselors felt prepared to handle cases of incidental findings related to maternal 
mosciasm of 45,XO (Turner Syndrome). This result was expected because of the low-stakes nature 
of this incidental finding. The surprising result related to this scenario was the frequency with 
which this incidental finding had been encountered in a sample size of 186 respondents. Several 
participants mentioned that age-related loss of an X chromosome is very common, making them 
less suspicious that the patient’s mosaicism would have medical implications. Others commented 
that it could have been a twin pregnancy, and early demise of a 45,X fetus could explain the 
discordant testing results. While these explanations cannot be ruled out, the focus of this study was 
to examine responses to incidental findings. 
Scenario 2: Maternal condition 
In Scenario 2, 9% of respondents answered that they would only recommend further genetic testing 
if there were clinical suspicion of maternal 22q11.2 deletion syndrome. 22q11.2 deletion syndrome 
is highly variable, and the possibility that a patient may be affected with this condition cannot be 
ruled out based solely on genetic counselors’ observations. 22q11.2 is a medically actionable 
condition in which patients would benefit in knowing their diagnosis. Missing opportunities to 
make a genetic diagnosis can have serious implications for both the patient and their pregnancies  
Like Scenario 1, it was surprising to hear about direct experiences with incidental findings 
of maternal cases of microdeletions and duplications of 22q. When this survey was released, it was 
thought that the anticipated small sample size would yield few to no genetic counselors with 
experiences similar to this scenario. The open-ended responses to this scenario proved otherwise. 
In addition, many counselors relied on the low positive predictive value of the test for this type of 
finding as the explanation for the result. However, if the cause of a false positive is never 
investigated, it is possible that genetic counselors are missing adult women with this condition. 
Scenario 3: Maternal malignancy 
This scenario had a steep drop in survey participation when compared to Scenario 1 and 2; about 
two thirds of the people who responded to Scenarios 1 and 2 did not complete Scenario 3. One 
possible explanation is that participants found this scenario more challenging than the first two, 
and were not interested in spending the necessary time to consider the case.  The genetic 
counselors who felt the least prepared to handle this situation were likely the ones who did not 
complete the survey. If this explanation is true, the results for Scenario 3 would overrepresent 
preparedness of the field.    
Limitations of the study  
There were several limitations to this study, the first being sample size. This was especially 
impactful for the third scenario, which only elicited 52 responses. This may have been due to the 
length of the survey (this was the final question set), or the challenging subject matter. Regardless, 
there was a precipitous drop-off in participation compared to the 150 and 145 people who 
responded to the first and second scenario, respectively.  
In addition, announcing that the topic of study was incidental findings may have 
predisposed participants to be extra sensitive to incidental findings in the hypothetical scenarios 
and to entice those with particular interest or competence in navigating incidental findings to 
participate. It is possible that many participants would have dismissed the scenarios as false 
positives, but because these cases were presented in the context of incidental findings research, 
they viewed them in that light. The suggestion bias may mean that these results do not truly 
represent how genetic counselors would respond to these scenarios in an actual clinical setting.  
Another limitation to this study is the diversity of clinic structures present in this sample. 
Although it is useful to represent the field of prenatal genetics broadly, institutional restrictions 
may have influenced participants’ answers. For example, genetic counselors in this study used a 
wide variety of genetic testing companies. Different labs have different policies; some laboratories 
are more liberal in communicating suspicions of incidental findings, whereas others are more 
conservative. While the choice of which lab to use may be dictated by external forces, it still shapes 
a genetic counselor’s past experience and current preparedness for incidental findings.  
Research Recommendations 
The majority of the genetic counselors in this study have encountered an incidental finding via 
NIPT, which suggests the prevalence is much higher than previously reported. As the use of NIPT 
increases and more conditions are added to the screening platforms, challenges of incidental 
findings will only increase in number, scope, and complexity. Research is needed to generate 
guidelines for practice in light of the possibility of discordant results and incidental findings. This 
may come in the form of counseling the patient about the possibility of discordant results during 
the informed consent process, or having standardized protocols for results disclosure and follow-
up testing.  More research needs to be done to determine the best method for following up on 
discordant NIPT results suggestive of incidental findings. A survey of patient experiences would 
be particularly useful, as would statistics showing the percentage of discordant results which are 
due to incidental findings of maternal origin.  
 
Conclusion 
As with all new technologies, implementation of NIPT has been accompanied by unexpected 
challenges. This study describes genetic counselors’ experiences with and responses to incidental 
findings from NIPT, including maternal mosaicism, maternal 22q11.2 deletion syndrome, and 
maternal malignancy. The results highlight steps which could be taken to ensure genetic counselors 
are prepared to handle these difficult situations. Genetic counselors benefit from having experience 
counseling a patient about incidental findings first-hand, reviewing the literature, and performing 
pre-testing counseling about specific types of incidental findings. In addition, genetic counselors 
who cited rarity as their reason for not discussing incidental findings during pretest counseling felt 
less prepared. Increasing awareness of this possibility may change this perception of rarity and 
make genetic counselors more prepared for these scenarios. 
The biggest barrier to pretest counseling about incidental findings is the perception that 
incidental findings are too rare to be a major concern and therefore do not warrant additional time 
spent discussing the possibility during the informed consent process. Time with patients is already 
limited and counselors try to keep sessions focused on the most relevant topics. However, this 
study suggests that it may be important for both the patient and the genetic counselor to discuss 
specific incidental findings that may occur during NIPT testings. Patients may benefit from 
knowing that unexpected information about their health may be discovered through prenatal 
screening. Genetic counselors may benefit by increasing their feeling of preparedness to manage 
incidental findings should they occur.  
While this study did not specifically set out to collate first-hand experiences with incidental 
findings, it did find that genetic counselors have seen each one of these scenarios play out in their 
clinics. The positive predictive value of NIPT results helps determine the real risk of the pregnancy 
being affected, but fails to explain why a false positive result was positive in the first place. This 
study gives some insights to why that may be and how genetic counselors are responding to these 
types of results.  
Genetic counseling as a profession has not arrived at a consensus on how to handle 
incidental findings from NIPT, and in general, genetic counselors do not feel adequately prepared 
to respond to them. As shown by the responses to the three hypothetical scenarios, feelings of 
preparedness decreased as the stakes of the findings increased; genetic counselors felt the least 
prepared to respond to maternal malignancy, the most significant finding with respect to the 
mother’s health.  
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Appendix 
Scenario 1: Maternal mosaicism 
A 37yo pregnant woman is referred for genetic counseling due to advanced maternal age. After 
counseling, she decides to undergo NIPT; the results are reported as high risk for Turner Syndrome 
(45,X) and you counsel the patient on the characteristics of Turner syndrome and confirmation by 
diagnostic testing. The patient decides to pursue an amniocentesis for confirmation; the results of the 
fetal karyotype are normal female (46,XX).  
 
In this scenario the possibility of NIPT revealing maternal mosaicism for XO (Turner’s syndrome) 
was introduced. As mentioned in Wang et al. 2014, there is a small but significant portion of 
discordant sex chromosome aneuploidy results through NIPT that can be attributed to maternal 
origins. This scenario is low stakes because maternal mosaicism for XO is relatively common in 
older women who lose an X chromosome with age with no health implications. There is a small 
risk for future pregnancies to be affected if the mosaicism is in the germline cells. 
Scenario 2: Maternal condition 
A 25yo pregnant woman is referred for routine prenatal genetic counseling at 11 weeks and decides to 
undergo NIPT. Her results are reported as high risk for 22q11.2 deletion syndrome. You call her with the 
results and ask her to return for a follow-up appointment. The patient opts for a microarray via CVS to 
confirm the result. The microarray returns normal for all conditions.   
 
This scenario was chosen because of the nature of 22q11.2 deletion syndrome, in that its phenotype 
can widely range within the same family, and although it is mostly found de novo, it can be passed 
through families. It is conceivable that a mother may get to child raising years and not know that 
she has this syndrome due to a milder phenotype. This scenario increases the stakes because a 
diagnosis of 22q11.2 would change reproductive options, specifically future pregnancies would be 
at a 50% risk for this condition and because of its range of presentation would be at risk of being 
more serious than the mother’s phenotype. There would also likely be new medical 
management/surveillance of the mother for cardiac defects and other abnormalities associated with 
this condition. Psychosocial considerations would also be in play. 
Scenario 3: Maternal malignancy 
A 40yo pregnant woman at 11 weeks gestation is referred for genetic counseling due to advanced 
maternal age. Nervous about being “too old”, the patient opts for NIPT. The NIPT reports a high risk for 
monosomy 13 and trisomy 18. You call the patient and ask her to return for a follow-up appointment.  A 
recent ultrasound revealed no fetal anomalies. The patient undergoes a CVS which reports a normal 
karyotype.  
 
This scenario was designed to examine genetic counselors’ responses to NIPT revealing possible 
maternal malignancy. Compared to the first two, this situation has more serious medical 
implications, and fewer established guidelines for management. For example, in the second 
scenario, if the genetic counselor suspected that the patient had 22q11.2 deletion syndrome, there 
is a clear way to confirm that suspicion (maternal FISH or microarray). Conversely, there is no 
clear way to determine whether the patient truly does have cancer; there is no obvious follow up 
which would rule out all possible malignancies. Because of the high stakes and the lack of 
confirmatory testing, scenario 3 was hypothesized to be the one for which genetic counselors are 
the least prepared.  
 
